{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-25-000108","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.881495+00:00","generated_at":"2026-05-17T00:38:02.132834+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia Q3 revenue $73.5M (+8%), net income $31.6M; LUPKYNIS sales up 27% YoY, FY guidance raised","bullets":["Q3 2025 net product sales of LUPKYNIS $70.6M, up 27% YoY; 9-month $197.2M, up 24%.","Diluted EPS $0.23 (Q3), up 130% YoY; net income $31.6M, up 119%.","FY 2025 net product sales guidance raised to $265-270M from $250-260M; total revenue guidance raised to $275-280M.","Cash from operating activities $44.5M in Q3, up 162% YoY; cash position $351.8M.","Positive Phase 1 results for aritinercept (BAFF/APRIL inhibitor); clinical studies in two autoimmune diseases planned by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-25-000108","json":"https://secwatch.observer/filing/0001600620-25-000108.json","markdown":"https://secwatch.observer/filing/0001600620-25-000108.md","text":"https://secwatch.observer/filing/0001600620-25-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000108/0001600620-25-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000108/auph-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:38:02.132834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}